Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263350, C514S263360
Reexamination Certificate
active
06878715
ABSTRACT:
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula:Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S. Each R1, R2and R3is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
REFERENCES:
patent: 4515795 (1985-05-01), Hinze et al.
patent: 5039666 (1991-08-01), Novick, Jr.
patent: 5629423 (1997-05-01), Klein et al.
patent: 5648357 (1997-07-01), Bianco et al.
patent: 5734051 (1998-03-01), Spicer et al.
patent: 5801182 (1998-09-01), Klein et al.
patent: 5807861 (1998-09-01), Klein et al.
patent: 6103730 (2000-08-01), Klein et al.
patent: 6133274 (2000-10-01), Underiner et al.
patent: 0 389 282 (1990-09-01), None
patent: WO9422449 (1994-10-01), None
patent: WO9422863 (1994-10-01), None
patent: WO9424133 (1994-10-01), None
patent: WO9520589 (1995-08-01), None
patent: WO9522546 (1995-08-01), None
“Development of Th1 CD4+T Cells Through IL-12 Produced byListeria-Induced Macrophages”, by Hsieh et al., Science, vol. 260, Apr. 23, 1993, pp. 547-549.
“Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)- specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells”, by Manetti et al., Journal of Exp. Medicine, vol. 177, Apr. 1993, pp. 1199-1204.
“Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effect on Human Lymphocytes”, by Kobayashi et al., Journal of Exp. Medicine, vol. 170, Sep. 1989, pp. 827-846.
“Interleukin 12: A Key Modulator of Immune Function”, by Wolf et al., Stem Cells, vol. 12, 1994, pp. 154-168.
“Internleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity”, by Trinchieri, Annu. Rev. Immunol., vol. 13, 1995, pp. 251-276.
“The Role of Cytokines on Various Animal Models of Inflammation”, by Heremans et al., Lymphokine Research, vol. 8, No. 3, 1989, pp. 329-333.
“Inducible Cell Contact Signals Regulate Early Activation Gene Expression During B-T Lymphocyte Collaboration”, by Klaus et al., The Journal of Immunology, vol. 49, No. 6, Sep. 1992, pp. 1867-1875.
“Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Required for In Vitro Generation of IL-4-producing Cells”, by Le Gros, et al., The Journal of Experimental Medicine, vol. 172, Sep. 1990, pp. 921-929.
“Inhibition of Human Interleukin-12 Production by Pentoxifylline”, by Moller et al., Immunology, vol. 91, 1997, pp. 197-203.
“The Immunology of Mutliple Sclerosis and its Animal Model, Experimental Allergic Encephalomyelitis”, by Owens et al., Neurologic Clinics, vol. 13, No. 1, Feb. 1995.
“Interleukin 12”, R& D Systems Catalog, pp. 67-69, 1995.
“Long-term Treatment of Chronic Relapsing Experimental Allergic Encephalomyelitis by Transforming Growth Factor-β2”, by Racke et al., Journal of Neuroimmunology, vol. 46, 1993, pp. 175-184.
“Phosphodiesterase Inhibitor Pentoxifylline, a Selective Suppressor of T Helper Type 1- but not Type 2-associated Lymphokine Production, Prevents Induction of Experimental Autoimmune Encephalomyelitis in Lewis Rats”, by Rott et al., Eur. J. Immumol., vol. 23, 1993, pp. 1745-1751.
“The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases”, by Trembleau et al., Immunology Today, vol. 16, No. 8, 1995, pp. 383-386.
Remington Pharmaceutical Sciences, Chapters 83-92, 1990, pp. 1519-1751.
Gong Baoqing
Klaus Stephen J.
Klein J. Peter
Kumar Anil M.
Cell Therapeutics Inc.
Nixon & Vanderhye P.C.
Wang Shengjun
LandOfFree
Therapeutic compounds for inhibiting interleukin-12 signals... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds for inhibiting interleukin-12 signals..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds for inhibiting interleukin-12 signals... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3366727